List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8576388/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The bleeding risk treatment paradox at the physician and hospital level: Implications for reducing bleeding in patients undergoing percutaneous coronary intervention. American Heart Journal, 2022, 243, 221-231.	2.7	2
2	In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). American Journal of Cardiology, 2022, 162, 24-30.	1.6	4
3	Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. American Heart Journal, 2022, 245, 29-40.	2.7	4
4	Percutaneous Coronary Intervention Operator Profiles and Associations With In-Hospital Mortality. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010909.	3.9	2
5	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
6	Trends in Arterial Access Site Selection and Bleeding Outcomes Following Coronary Procedures, 2011–2018. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121008359.	2.2	11
7	RESPONSE: Navigating the Transition From Fellowship to Early Career. Journal of the American College of Cardiology, 2022, 79, 1218-1219.	2.8	0
8	Heart Team Without Borders: Taking the Heart Team Beyond the Institution. Journal of the American Heart Association, 2022, 11, e025080.	3.7	0
9	Review of Cardiogenic Shock After Acute Myocardial Infarction—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 879.	7.4	2
10	Prophylactic Mechanical Circulatory Support Use in Elective Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2022, 15, e011534.	3.9	9
11	Systematic Review and Network Metaâ€Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, .	3.7	12
12	Algorithms for challenging scenarios encountered in transradial intervention. Indian Heart Journal, 2021, 73, 149-155.	0.5	0
13	Real-World Data on the Intravascular Microaxial Left Ventricular Flow Pump (Impella) in High-Risk Patients. Korean Circulation Journal, 2021, 51, 487.	1.9	0
14	2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 77, 811-825.	2.8	34
15	The association between coronary graft patency and clinical status in patients with coronary artery disease. European Heart Journal, 2021, 42, 1433-1441.	2.2	32
16	Ventricular Fibrillation Due to Aortocoronary Vein Graft Spasm During Angiography. JACC: Case Reports, 2021, 3, 388-391.	0.6	2
17	Characteristics and Outcomes of Patients With History of CABG Undergoing Cardiac Catheterization Via the Radial Versus Femoral Approach. JACC: Cardiovascular Interventions, 2021, 14, 907-916.	2.9	7
18	Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation, 2021, 143, e815-e829.	1.6	103

#	Article	IF	CITATIONS
19	Evidenceâ€based arterial access site practice in patients with acute coronary syndromes: Has SAFARIâ€STEMI changed the landscape?. Catheterization and Cardiovascular Interventions, 2021, 97, 1417-1421.	1.7	0
20	Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. American Heart Journal, 2021, 235, 149-157.	2.7	3
21	Interventional cardiologists' perceptions of percutaneous coronary intervention quality measurement and feedback. American Heart Journal, 2021, 235, 97-103.	2.7	8
22	Coronary Artery Disease Evaluation and Management Considerations for High Risk Occupations: Commercial Vehicle Drivers and Pilots. Circulation: Cardiovascular Interventions, 2021, 14, e009950.	3.9	7
23	Quo Vadis, Bleeding Risk Models?. JACC: Cardiovascular Interventions, 2021, 14, 1207-1208.	2.9	0
24	Transradial Access for High-Risk Percutaneous Coronary Intervention: Implications of the Risk-Treatment Paradox. Circulation: Cardiovascular Interventions, 2021, 14, e009328.	3.9	8
25	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	5.9	5
26	Venous thromboembolism among patients hospitalized with COVID-19 at Veterans Health Administration Hospitals. American Heart Journal, 2021, 237, 1-4.	2.7	3
27	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010458.	3.9	2
28	Trends in Use and Outcomes of Same-Day Discharge Following Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2021, 14, 1655-1666.	2.9	14
29	Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e107-e119.	1.6	26
30	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 1550-1563.	2.8	16
31	Design and baseline results of a coaching intervention for implementation of trans-radial access in percutaneous coronary intervention. Contemporary Clinical Trials, 2021, 111, 106606.	1.8	1
32	Cost analysis of a coaching intervention to increase use of transradial percutaneous coronary intervention. Implementation Science Communications, 2021, 2, 123.	2.2	1
33	Cardiogenic Shock After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2021, 326, 1840.	7.4	121
34	Hospital-Level Percutaneous Coronary Intervention Performance With SimulatedÂRisk Avoidance. Journal of the American College of Cardiology, 2021, 78, 2213-2217.	2.8	1
35	Radial versus femoral access in patients with coronary artery bypass surgery: Frequentist and Bayesian metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	1
36	Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation, 2021, 144, 728-745.	1.6	75

#	Article	IF	CITATIONS
37	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2020, 95, 885-892.	1.7	5
38	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 96, E102-E109.	1.7	10
39	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. American Heart Journal, 2020, 219, 1-8.	2.7	27
40	SCAI expert consensus statement update on best practices for transradial angiography and intervention. Catheterization and Cardiovascular Interventions, 2020, 95, 245-252.	1.7	54
41	The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support. Circulation, 2020, 141, 273-284.	1.6	278
42	Radial Access for Peripheral Interventions. Interventional Cardiology Clinics, 2020, 9, 53-61.	0.4	5
43	Reduced radiation exposure in the cardiac catheterization laboratory with a novel vertical radiation shield. Catheterization and Cardiovascular Interventions, 2020, 95, 7-12.	1.7	10
44	Currently Available Options for Mechanical Circulatory Support for the Management of Cardiogenic Shock. Cardiology Clinics, 2020, 38, 527-542.	2.2	1
45	The State of Percutaneous Intervention in Stable Coronary Artery Disease. Current Atherosclerosis Reports, 2020, 22, 42.	4.8	0
46	Cardiac Imaging in the Post-ISCHEMIA Trial Era. JACC: Cardiovascular Imaging, 2020, 13, 1815-1833.	5.3	21
47	Cardiac safety research consortium "shock II―think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97.	2.7	14
48	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. Circulation: Cardiovascular Interventions, 2020, 13, e008603.	3.9	28
49	Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey. American Heart Journal, 2020, 225, 55-59.	2.7	3
50	Early vs Late Discharge in Low-Risk ST-Elevation Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2020, 21, 1360-1368.	0.8	7
51	Differential Use and Impact of Bleeding Avoidance Strategies on Percutaneous Coronary Intervention-Related Bleeding Stratified by Predicted Risk. Circulation: Cardiovascular Interventions, 2020, 13, e008702.	3.9	2
52	Splanchnic Nerve Block for ChronicÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 742-752.	4.1	44
53	Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. American Heart Journal, 2020, 223, 87-97.	2.7	17
54	Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis. American Heart Journal, 2020, 224, 98-104.	2.7	8

#	Article	IF	CITATIONS
55	Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008494.	3.9	11
56	Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008227.	3.9	49
57	Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. JAMA Cardiology, 2020, 5, 765.	6.1	10
58	A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. International Journal of Cardiology, 2020, 309, 95-99.	1.7	13
59	Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Critical Pathways in Cardiology, 2020, 19, 166-172.	0.5	1
60	Validation of the Academic Research Consortium Definition of High Bleeding Risk. Journal of the American College of Cardiology, 2020, 75, 2723-2725.	2.8	0
61	Abstract 16327: Clinical Profiles, Care Patterns, Outcomes and Sex Differences of Patients With STEMI in India: Insights From the North Indian ST-segment Elevation Myocardial Infarction (NORIN STEMI) Registry. Circulation, 2020, 142, .	1.6	0
62	Abstract 16946: Radial versus Femoral Access for Coronary Procedures in Patients With Prior Coronary Artery Bypass Grafting Surgery: An Updated Study-Level Meta-Analysis. Circulation, 2020, 142,	1.6	0
63	Safety and efficacy of radial versus femoral access for rotational Atherectomy: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 2019, 20, 241-247.	0.8	11
64	Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2019, 12, e007877.	3.9	22
65	Enhancement of Risk Prediction With Machine Learning. JAMA Network Open, 2019, 2, e196823.	5.9	3
66	Cath Lab Robotics: Paradigm Change in Interventional Cardiology?. Current Cardiology Reports, 2019, 21, 119.	2.9	15
67	Proposed Framework for the Optimal Measurement of Quality Assessment in Percutaneous Coronary Intervention. JAMA Cardiology, 2019, 4, 963.	6.1	8
68	The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale. American Heart Journal, 2019, 216, 82-90.	2.7	3
69	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 2019, 218, 110-122.	2.7	7
70	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	2.2	335
71	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
72	Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. American Heart Journal, 2019, 213, 47-56.	2.7	8

#	Article	IF	CITATIONS
73	Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circulation: Cardiovascular Interventions, 2019, 12, e007086.	3.9	6
74	Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 361-369.	4.0	11
75	Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. BMJ Open, 2019, 9, e023337.	1.9	13
76	RESPONSE: Establishing a Strong Foundation for Lifelong Learning. Journal of the American College of Cardiology, 2019, 73, 871-872.	2.8	0
77	Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial. American Heart Journal, 2019, 218, 84-91.	2.7	3
78	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019, 139, 458-472.	1.6	43
79	Contemporary transradial access practices: Results of the second international survey. Catheterization and Cardiovascular Interventions, 2019, 93, 1276-1287.	1.7	42
80	Bivalirudin with a postâ€procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheterization and Cardiovascular Interventions, 2019, 94, 210-215.	1.7	13
81	Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS. Current Cardiology Reports, 2019, 21, 3.	2.9	9
82	Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 93, 241-247.	1.7	6
83	Relation of Length of Stay to Unplanned Readmissions for Patients Who Undergo Elective Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 33-43.	1.6	11
84	Length of stay following percutaneous coronary intervention: An expert consensus document update from the society for cardiovascular angiography and interventions. Catheterization and Cardiovascular Interventions, 2018, 92, 717-731.	1.7	63
85	Post-Traumatic Stress Disorder and Heart Failure in Men Within the Veteran Affairs Health System. American Journal of Cardiology, 2018, 122, 275-278.	1.6	9
86	Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost. JACC: Cardiovascular Interventions, 2018, 11, 665-674.	2.9	49
87	Heparin use for diagnostic cardiac catheterization with a radial artery approach: An international survey of practice patterns. Catheterization and Cardiovascular Interventions, 2018, 92, 854-859.	1.7	7
88	Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005628.	3.9	7
89	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine, 2018, 19, 143-150.	0.8	2
90	Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Nonranked Hospitals inÂthe United States. JACC: Cardiovascular Interventions, 2018, 11, 342-350.	2.9	10

#	Article	IF	CITATIONS
91	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Canadian Journal of Cardiology, 2018, 34, 319-329.	1.7	22
92	Anemia and coronary artery disease. Coronary Artery Disease, 2018, 29, 161-167.	0.7	29
93	Relation Between Age and Unplanned Readmissions After Percutaneous Coronary Intervention (Findings from the Nationwide Readmission Database). American Journal of Cardiology, 2018, 122, 220-228.	1.6	10
94	Incidence, procedural management, and clinical outcomes of coronary inâ€stent restenosis: Insights from the National VA CART Program. Catheterization and Cardiovascular Interventions, 2018, 91, 425-433.	1.7	9
95	Percutaneous or surgical access for transfemoral transcatheter aortic valve implantation. Journal of Thoracic Disease, 2018, 10, S3595-S3598.	1.4	7
96	The Current State of Transradial Access: A Perspective on Transradial Outcomes, Learning Curves, and Same-Day Discharge. Cardiovascular Innovations and Applications, 2018, 3, .	0.3	1
97	Predictors and Outcomes of StagedÂVersus One-Time MultivesselÂRevascularization in MultivesselÂCoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2018, 11, 2265-2273.	2.9	9
98	A quality framework for the role of invasive, nonâ€interventional cardiologists in the presentâ€day cardiac catheterization laboratory: A multidisciplinary SCAI/HFSA expert consensus statement. Catheterization and Cardiovascular Interventions, 2018, 92, 1356-1364.	1.7	2
99	Cardiac allograft vasculopathy: A review. Catheterization and Cardiovascular Interventions, 2018, 92, E527-E536.	1.7	33
100	Association of Same-Day Discharge After Elective Percutaneous Coronary Intervention in the United States With Costs and Outcomes. JAMA Cardiology, 2018, 3, 1041.	6.1	65
101	Preventing Acute Radial Artery Occlusion. JACC: Cardiovascular Interventions, 2018, 11, 2251-2253.	2.9	3
102	The Future of Circulation: Cardiovascular Interventions. Circulation: Cardiovascular Interventions, 2018, 11, e007115.	3.9	0
103	Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet, The, 2018, 391, 1997-2007.	13.7	70
104	The Impact of a Rigorous Quality Program on 3D Echocardiography Data Quality in an International Multisite Randomized Trial. JACC: Cardiovascular Imaging, 2018, 11, 1918-1920.	5.3	0
105	Vascular Access for Left Heart Catheterization. , 2018, , 59-77.		0
106	Sexâ€related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheterization and Cardiovascular Interventions, 2017, 89, 629-637.	1.7	56
107	Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review. Journal of Thrombosis and Thrombolysis, 2017, 43, 519-527.	2.1	10
108	Comparative Efficacy of Coronary Revascularization Procedures for Multivessel Coronary Artery Disease in Patients With Chronic Kidney Disease. American Journal of Cardiology, 2017, 119, 1344-1351.	1.6	22

#	Article	IF	CITATIONS
109	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. American Heart Journal, 2017, 188, 73-81.	2.7	25
110	Polymer-Free Drug-Coated Coronary Stents in Patients with Stable Coronary Artery Disease at High Bleeding Risk. Current Cardiology Reports, 2017, 19, 12.	2.9	4
111	Bleeding and Mortality With Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2017, 69, 2023-2025.	2.8	3
112	Perioperative Management of Dual-Antiplatelet Therapy in Patients With New-Generation Drug-Eluting Metallic Stents and Bioresorbable Vascular Scaffolds Undergoing Elective Noncardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1857-1864.	1.3	7
113	Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to Endâ€6tage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization—An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program. Iournal of the American Heart Association. 2017. 6	3.7	22
114	Putting Prognosis Into Perspective. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	0
115	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
116	Outcomes in Patients Undergoing PrimaryÂPercutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin VersusÂHeparin. JACC: Cardiovascular Interventions, 2017, 10, 1102-1111.	2.9	12
117	Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement. Cardiovascular Revascularization Medicine, 2017, 18, 588-591.	0.8	1
118	Outcomes of PCI in Relation to ProceduralÂCharacteristics and OperatorÂVolumes inÂthe United States. Journal of the American College of Cardiology, 2017, 69, 2913-2924.	2.8	104
119	Use of Antiplatelet Therapy/DAPT forÂPost-PCI Patients Undergoing Noncardiac Surgery. Journal of the American College of Cardiology, 2017, 69, 1861-1870.	2.8	56
120	Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 672-682.	2.9	19
121	Variation in practice and concordance with guideline criteria for length of stay after elective percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2017, 90, 715-722.	1.7	22
122	The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 23.	4.8	33
123	Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease. American Journal of Cardiology, 2017, 119, 1942-1948.	1.6	21
124	Hospital Readmission as a Transcatheter Aortic Valve Replacement Performance Measure. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	2
125	Editorial: Navigating the rough seas of anemia; caught between the devil and the deep blue sea. Journal of Interventional Cardiology, 2017, 30, 500-501.	1.2	0
126	Variation in the Adoption of TransradialÂAccess for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 2242-2254.	2.9	53

#	Article	IF	CITATIONS
127	Rationale and design of the Drugâ€Eluting Stents vs Bareâ€Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial. Clinical Cardiology, 2017, 40, 946-954.	1.8	10
128	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes) Tj ETQq0 0 0 i	rgB 3.∤ Ove	rlock110 Tf 50
129	Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals. JAMA Cardiology, 2017, 2, 967.	6.1	27
130	Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. Journal of Thrombosis and Thrombolysis, 2017, 44, 303-315.	2.1	5
131	Complete Coronary Revascularization. JACC: Cardiovascular Interventions, 2017, 10, 1425-1427.	2.9	Ο
132	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2017-2025.	2.9	41
133	Morbidity and Mortality Conference for Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	13
134	25 Years of Transradial Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2266-2268.	2.9	16
135	Transfemoral Approach for CoronaryÂAngiography and Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2269-2279.	2.9	32
136	Radial artery diameter does not correlate with body mass index: A duplex ultrasound analysis of 1706 patients undergoing trans-radial catheterization at three experienced radial centers. International Journal of Cardiology, 2017, 228, 169-172.	1.7	19
137	Transradial approach for coronary angiography and intervention in the elderly: A meta-analysis of 777,841 patients. International Journal of Cardiology, 2017, 228, 45-51.	1.7	54
138	Effect of postâ€primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network metaâ€analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions, 2017, 90, 196-204.	1.7	8
139	Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	41
140	Transradial PCI for Complex PCI: An Overview. , 2017, , 101-103.		0
141	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2016, 9, 1419-1434.	2.9	385
142	Characteristics, treatment and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. BMJ Open, 2016, 6, e012193.	1.9	15
143	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	3.9	41
144	Same-Day Discharge After Percutaneous Coronary Intervention. JAMA Cardiology, 2016, 1, 216.	6.1	69

#	Article	IF	CITATIONS
145	Percutaneous Coronary Intervention inÂNative Coronary Arteries Versus BypassÂGrafts in Patients With Prior Coronary Artery Bypass Graft Surgery. JACC: Cardiovascular Interventions, 2016, 9, 884-893.	2.9	122
146	Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2016, 9, 978-979.	2.9	4
147	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation inÂBleeding Rates Following PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 771-779.	2.9	17
148	Blood Transfusion and the Risk of Acute Kidney Injury Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	34
149	Clinical Practice Guidelines From the AABB. JAMA - Journal of the American Medical Association, 2016, 316, 2025.	7.4	871
150	The Fuzzy Math of Anticoagulation andÂAccess Site. JACC: Cardiovascular Interventions, 2016, 9, 1532-1534.	2.9	4
151	Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 715-723.	2.8	79
152	SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia) Tj ETQq0 0 0 rgB	T /Overlock 1.7	2 10 Tf 50 46 78
153	Cardiovascular Interventions, 2016, 88, 407-423 Safety and clinical effectiveness of druga€eluting stents for saphenous vein graft intervention in older individuals: Results from the medicareâ€inked National Cardiovascular Data Registry [®] Cath <scp>PCI</scp> Registry [®] (2005–2009). Catheterization and Cardiovascular Interventions, 2016, 87, 43-49.	1.7	16
154	Arterial access and arteriotomy site closure devices. Nature Reviews Cardiology, 2016, 13, 641-650.	13.7	30
155	Controversies in the Management of ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics, 2016, 5, 513-522.	0.4	0
156	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 68, 1898-1907.	2.8	75
157	A teamâ€based approach to patients in cardiogenic shock. Catheterization and Cardiovascular Interventions, 2016, 88, 424-433.	1.7	67
158	Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheterization and Cardiovascular Interventions, 2016, 88, 163-173.	1.7	7
159	Effect of Post–Primary Percutaneous Coronary Intervention Bivalirudin InfusionÂon Acute Stent Thrombosis. JACC: Cardiovascular Interventions, 2016, 9, 1313-1320.	2.9	24
160	CASE 11—2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1698-1708.	1.3	2
161	An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. American Heart Journal, 2016, 171, 14-24.	2.7	46
162	Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 117, 1256-1266.	1.6	16

#	Article	IF	CITATIONS
163	Characteristics of Patients Undergoing Cardiac Catheterization Before Noncardiac Surgery. JAMA Internal Medicine, 2016, 176, 611.	5.1	17
164	Antiplatelet Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 221-237.	0.4	5
165	Anticoagulation in coronary intervention. European Heart Journal, 2016, 37, 3376-3385.	2.2	37
166	Post-procedural/pre-hemostasis intra-arterial nitroglycerin after transradial catheterization: A gender based analysis. Cardiovascular Revascularization Medicine, 2016, 17, 10-14.	0.8	4
167	SCAI: Enhancing patient care through quality. Catheterization and Cardiovascular Interventions, 2015, 86, 1-2.	1.7	6
168	<scp>SCAI</scp> core curriculum for adult and pediatric interventional fellowship training in continuous quality assessment and improvement. Catheterization and Cardiovascular Interventions, 2015, 86, 422-431.	1.7	8
169	Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a Highâ€Risk Population. Journal of the American Heart Association, 2015, 4, .	3.7	1
170	Blood Transfusion After Percutaneous Coronary Intervention and Risk of Subsequent Adverse Outcomes. JACC: Cardiovascular Interventions, 2015, 8, 436-446.	2.9	58
171	Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e001403.	3.9	47
172	Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. American Heart Journal, 2015, 170, 1227-1233.	2.7	21
173	Transradial Versus Transfemoral Access inÂPatients Undergoing Rescue Percutaneous Coronary Intervention AfterÂFibrinolytic Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1868-1876.	2.9	17
174	The Multidimensionality of CardiovascularÂProcedures â^—. Journal of the American College of Cardiology, 2015, 66, 2869-2871.	2.8	2
175	Proficiency With Vascular Access. JACC: Cardiovascular Interventions, 2015, 8, 1865-1867.	2.9	6
176	Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 15-22.	2.2	13
177	Radial Artery Occlusion After Transradial Approach to Cardiac Catheterization. Current Atherosclerosis Reports, 2015, 17, 489.	4.8	48
178	Current State of Radial Artery Catheterization in ST-Elevation Myocardial Infarction. Progress in Cardiovascular Diseases, 2015, 58, 241-246.	3.1	10
179	A comparison of radial and femoral access for cardiac catheterization. Trends in Cardiovascular Medicine, 2015, 25, 707-713.	4.9	14
180	Radial Versus Femoral Access for CoronaryÂAngiography/Intervention in Women With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2015, 8, 505-512.	2.9	73

#	Article	IF	CITATIONS
181	Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8,	3.9	17
182	Radial Approach: Fundamental Techniques and Evidence. Interventional Cardiology Clinics, 2015, 4, ix.	0.4	0
183	Access and Non–Access Site Bleeding After Percutaneous Coronary Intervention and Risk of Subsequent Mortality and Major Adverse Cardiovascular Events. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	95
184	Approaching the Post-Femoral Era for Coronary Angiography and Intervention. JACC: Cardiovascular Interventions, 2015, 8, 524-526.	2.9	6
185	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, The, 2015, 385, 2465-2476.	13.7	1,043
186	Registry-based randomized clinical trials—a new clinical trial paradigm. Nature Reviews Cardiology, 2015, 12, 312-316.	13.7	236
187	The choice of arterial access for percutaneous coronary intervention and its impact on outcome: An expert opinion perspective. American Heart Journal, 2015, 170, 13-22.	2.7	9
188	Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. American Heart Journal, 2015, 170, 371-379.	2.7	37
189	Hospital Length of Stay and ClinicalÂOutcomes in Older STEMI PatientsÂAfter Primary PCI. Journal of the American College of Cardiology, 2015, 65, 1161-1171.	2.8	72
190	The Conundrum of Reducing Ischemic andÂBleeding Events After PCI. Journal of the American College of Cardiology, 2015, 65, 1421-1423.	2.8	11
191	Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2015, 386, 2192-2203.	13.7	115
192	A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. American Heart Journal. 2015, 170, 929-937.	2.7	39
193	Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention: A systematic review and meta-analysis. American Heart Journal, 2015, 170, 353-361.e6.	2.7	56
194	Transfusion in Ischemic Heart Disease. Journal of the American College of Cardiology, 2015, 66, 2519-2521.	2.8	4
195	Same day discharge following transradial PCI in India: Creating value for patients and providers. Indian Heart Journal, 2015, 67, 90-92.	0.5	0
196	Reply. JACC: Cardiovascular Interventions, 2015, 8, 639.	2.9	0
197	De-implementing the Allen's Test. Journal of Invasive Cardiology, 2015, 27, E74.	0.4	0
198	Risk of Acute Kidney Injury After Percutaneous Coronary Interventions Using Radial Versus Femoral Vascular Access. Circulation: Cardiovascular Interventions, 2014, 7, 190-198.	3.9	74

#	Article	IF	CITATIONS
199	Mechanisms by Which Transradial Approach May Reduce Mortality in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 621-627.	3.9	5
200	Patterns and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2014, 311, 836.	7.4	72
201	Perceptions of advantages and barriers to radial-access percutaneous coronary intervention in VA cardiac catheterization laboratories. Cardiovascular Revascularization Medicine, 2014, 15, 329-333.	0.8	17
202	Balloonâ€assisted tracking: A mustâ€know technique to overcome difficult anatomy during transradial approach. Catheterization and Cardiovascular Interventions, 2014, 83, 211-220.	1.7	84
203	Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensityâ€Matched Study. Clinical Cardiology, 2014, 37, 14-20.	1.8	3
204	Primary non-interventional operator vascular access choice is associated with lower use of radial PCI: insights from the VA CART. Cardiovascular Revascularization Medicine, 2014, 15, 439-441.	0.8	0
205	Best practices for transradial angiography and intervention: A consensus statement from the society for cardiovascular angiography and intervention's transradial working group. Catheterization and Cardiovascular Interventions, 2014, 83, 228-236.	1.7	170
206	The Learning Curve for Transradial Percutaneous Coronary Intervention Among Operators in the United States. Circulation, 2014, 129, 2277-2286.	1.6	156
207	Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 550-559.	2.2	47
208	Improving outcomes in primary percutaneous coronary intervention: Transradial is worth the time. American Heart Journal, 2014, 168, 1-3.	2.7	9
209	Isn't It About Time We Learned How to Use Blood Transfusion in Patients With Ischemic Heart Disease?. Journal of the American College of Cardiology, 2014, 63, 1297-1299.	2.8	8
210	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European Heart Journal, 2014, 35, 2524-2529.	2.2	49
211	A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20–200ng/mL. Blood Cells, Molecules, and Diseases, 2014, 53, 221-230.	1.4	12
212	Staying ahead of the curve. Cardiovascular Revascularization Medicine, 2014, 15, 193-194.	0.8	0
213	Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. Open Heart, 2014, 1, e000021.	2.3	99
214	Baseline Bleeding Risk and Benefit ofÂTransradial PCI. Journal of the American College of Cardiology, 2014, 64, 1565-1567.	2.8	1
215	Bleeding Complications After PCI and the Role of Transradial Access. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 305.	0.9	8
216	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 857-867.	2.9	223

ARTICLE IF CITATIONS Minimizing femoral artery access complications during percutaneous coronary intervention: A comprehensive review. Catheterization and Cardiovascular Interventions, 2014, 84, 62-69. Vascular Access, Closure, and Management., 2014, , 65-77. 218 2 Prognostic Significance of Bleeding Location and Severity Among Patients With Acute Coronary 219 Syndromes. JACC: Cardiovascular Interventions, 2013, 6, 709-717. Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial 220 2.8 170 Infarction. Journal of the American College of Cardiology, 2013, 62, 2000-2007. Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States. American Heart Journal, 2013, 166, 273-281.e4. 2.7 Patterns of Use and Comparative Effectiveness of Bleeding Avoidance Strategies in Men and Women 222 Following Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2.8 73 2013, 61, 2070-2078. An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing 2.9 229 Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 897-904. Enhanced Mortality Risk Prediction With a Focus on High-Risk Percutaneous Coronary Intervention. 224 2.9 162 JACC: Cardiovascular Interventions, 2013, 6, 790-799. Radial versus femoral access, bleeding and ischemic events in patients with non–ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal, 2013, 165, 583-590.e1. 226 Blood transfusion in patients with acute MI and anaemia. Nature Reviews Cardiology, 2013, 10, 186-187. 13.7 11 Reply. Journal of the American College of Cardiology, 2013, 61, 2394. 2.8 Same-Day Discharge Compared With Overnight Hospitalization After Uncomplicated Percutaneous 228 2.9 93 Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 99-112. Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume. JACC: Cardiovascular Interventions, 2013, 6, 258-266. Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary 230 2.7 71 Intervention for Women (SAFE-PCÍ for Women). American Heart Journal, 2013, 166, 421-428.e1. Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with nonâ€"ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches. American Heart Journal, 2013, 165, 644-654.e1. The Value Proposition in Percutaneous Coronary Interventiona[^] –. JACC: Cardiovascular Interventions, 232 2.9 3 2013, 6, 835-837. Improving outcomes in patients with cardiogenic shock: Achieving more through less. American Heart 2.7 Journal, 2013, 165, 256-257. The Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment 2.8 149

SUNIL V RAO

234 Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 420-426.

#	Article	IF	CITATIONS
235	Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal, 2013, 165, 964-971.e1.	2.7	317
236	Adoption of Transradial Percutaneous Coronary Intervention and Outcomes According to Center Radial Volume in the Veterans Affairs Healthcare System. Circulation: Cardiovascular Interventions, 2013, 6, 336-346.	3.9	35
237	Progression of radial approach to PCI in the USA: from niche procedure to default approach. Expert Review of Cardiovascular Therapy, 2013, 11, 1271-1273.	1.5	4
238	Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention. Circulation, 2013, 127, 2295-2306.	1.6	406
239	Comparison of Bivalirudin and Radial Access Across a Spectrum of Preprocedural Risk of Bleeding in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 347-353.	3.9	32
240	Radial First: Paradox+Proficiency=Opportunity. Journal of the American Heart Association, 2013, 2, e000281.	3.7	8
241	Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2013, 309, 1022.	7.4	235
242	Arterial and Venous Access and Hemostasis for PCI. , 2013, , 38-82.		1
243	Short- and Long-Term Outcomes of Coronary Stenting in Women Versus Men. Circulation, 2012, 126, 2190-2199.	1.6	77
244	Association of Bleeding and In-Hospital Mortality in Black and White Patients With ST-Segment–Elevation Myocardial Infarction Receiving Reperfusion. Circulation, 2012, 125, 1727-1734.	1.6	28
245	Evaluating the Bite of the BARC. Circulation, 2012, 125, 1344-1346.	1.6	8
246	The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. European Heart Journal, 2012, 33, 2044-2053.	2.2	71
247	Remaining challenges and opportunities for improvement in percutaneous transradial coronary procedures. European Heart Journal, 2012, 33, 2521-2526.	2.2	78
248	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine, 2012, 157, 49.	3.9	920
249	Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation. Journal of the American College of Cardiology, 2012, 60, 2490-2499.	2.8	349
250	Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation. Advances in Cardiology, 2012, 47, 125-140.	2.7	0
251	Comparison of transradial and femoral approaches for percutaneous coronary interventions: A systematic review and hierarchical Bayesian meta-analysis. American Heart Journal, 2012, 163, 632-648.	2.7	230
252	Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 110, 599-606.	1.6	36

#	Article	IF	CITATIONS
253	Temporal Trends in and Factors Associated With Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 1861-1869.	2.8	129
254	Observations From a Transradial Registry. JACC: Cardiovascular Interventions, 2012, 5, 44-46.	2.9	14
255	Association Between Periprocedural Bleeding and Long-Term Outcomes Following Percutaneous Coronary Intervention in Older Patients. JACC: Cardiovascular Interventions, 2012, 5, 958-965.	2.9	79
256	Clinical expert consensus statement on best practices in the cardiac catheterization laboratory: Society for cardiovascular angiography and interventions. Catheterization and Cardiovascular Interventions, 2012, 80, 456-464.	1.7	56
257	Radial Versus Femoral Access for Percutaneous Coronary Intervention: Implications for Vascular Complications and Bleeding. Current Cardiology Reports, 2012, 14, 502-509.	2.9	59
258	Bleeding Avoidance Strategies. Journal of the American College of Cardiology, 2011, 58, 1-10.	2.8	152
259	Percutaneous Coronary Intervention in Native Arteries Versus Bypass Grafts in Prior Coronary Artery Bypass Grafting Patients. JACC: Cardiovascular Interventions, 2011, 4, 844-850.	2.9	170
260	Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal, 2011, 161, 254-260.e4.	2.7	46
261	Trends and predictors of length of stay after primary percutaneous coronary intervention: A report from the CathPCI Registry. American Heart Journal, 2011, 162, 1052-1061.	2.7	25
262	Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. American Journal of Medicine, 2011, 124, 48-57.	1.5	31
263	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, The, 2011, 377, 1409-1420.	13.7	1,759
264	Bleeding and Acute Coronary Syndromes: Defining, Predicting, and Managing Risk and Outcomes. Current Drug Targets, 2011, 12, 1831-1835.	2.1	8
265	The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. Clinical Investigation, 2011, 1, 1155-1165.	0.0	0
266	Conservative Versus Liberal Red Cell Transfusion in Acute Myocardial Infarction (the CRIT Randomized) Tj ETQqO	0 0 rgBT /0 1.6	Overlock 10
267	Atrial Fibrillation and Percutaneous Coronary Intervention: Stroke, Thrombosis, and Bleeding. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 203-214.	0.9	1
268	Quality assessment and improvement in interventional cardiology: A position statement of the Society of Cardiovascular Angiography and Interventions, part 1: Standards for quality assessment and improvement in interventional cardiology. Catheterization and Cardiovascular Interventions, 2011, 77, 927-935.	1.7	34
269	Transradial arterial access for coronary and peripheral procedures: Executive summary by the transradial committee of the SCAI. Catheterization and Cardiovascular Interventions, 2011, 78, 823-839.	1.7	253

Quality assessment and improvement in interventional cardiology: A position statement of the society270of cardiovascular angiography and interventions, Part II: Public reporting and risk adjustment.1.725Catheterization and Cardiovascular Interventions, 2011, 78, 493-502.1.725

#	Article	IF	CITATIONS
271	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 191-197.	2.9	229
272	Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2011, 4, 463-473.	3.9	25
273	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
274	Operator Radiation Exposure During Percutaneous Coronary Procedures Through the Left or Right Radial Approach. Circulation: Cardiovascular Interventions, 2011, 4, 226-231.	3.9	46
275	Prevalence and Outcomes of Same-Day Discharge After Elective Percutaneous Coronary Intervention Among Older Patients. JAMA - Journal of the American Medical Association, 2011, 306, 1461.	7.4	95
276	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2011, 32, 1854-1864.	2.2	343
277	Bleeding in the Acute Coronary Syndromes. , 2011, , 322-329.		0
278	Transradial PCI in women: problem solved or clinical equipoise?. Journal of Invasive Cardiology, 2011, 23, 4 p preceding 101.	0.4	0
279	Association Between Use of Bleeding Avoidance Strategies and Risk of Periprocedural Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2010, 303, 2156.	7.4	264
280	Cost-Effectiveness of Targeting Patients Undergoing Percutaneous Coronary Intervention for Therapy With Bivalirudin Versus Heparin Monotherapy According to Predicted Risk of Bleeding. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 358-365.	2.2	35
281	Acceptance, Panic, and Partial Recovery. JACC: Cardiovascular Interventions, 2010, 3, 902-910.	2.9	35
282	Transradial Approach for Coronary Angiography and Interventions. JACC: Cardiovascular Interventions, 2010, 3, 1022-1031.	2.9	335
283	Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms?. Journal of Thrombosis and Thrombolysis, 2010, 30, 332-339.	2.1	12
284	The Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 1209-1219.	2.9	42
285	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. European Heart Journal, 2010, 31, 227-235.	2.2	59
286	Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years. Circulation: Cardiovascular Interventions, 2010, 3, 140-147.	3.9	69
287	Anticoagulant Therapy for Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 80-88.	3.9	75
288	Scaling New Heights in Quality Improvement. Journal of the American College of Cardiology, 2010, 56, 15-17.	2.8	5

#	Article	IF	CITATIONS
289	The Transradial Approach to Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 55, 2187-2195.	2.8	299
290	Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 55, 1923-1932.	2.8	404
291	Hemorrhage in Patients With Acute Coronary Syndrome: From Annoying Observation to Major Challenge. Revista Espanola De Cardiologia (English Ed), 2010, 63, 1-4.	0.6	1
292	Is old blood bad blood?. American Heart Journal, 2010, 159, 710-712.	2.7	11
293	Rapid adoption of drug-eluting stents: Clinical practices and outcomes from the early drug-eluting stent era. American Heart Journal, 2010, 160, 767-774.e1.	2.7	15
294	Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. American Heart Journal, 2010, 160, 1056-1064.e2.	2.7	19
295	Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention. Circulation, 2010, 121, 1713-1721.	1.6	21
296	The impact of bivalirudin on percutaneous coronary intervention-related bleeding. EuroIntervention, 2010, 6, 206-213.	3.2	18
297	Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2009, 2, 222-229.	3.9	278
298	Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non–ST-Segment–Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 414-420.	2.2	43
299	Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction. Circulation, 2009, 119, 1873-1882.	1.6	876
300	Prevalence, Predictors, and In-Hospital Outcomes of Non-Infarct Artery Intervention During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (from the) Tj ETQq0 0 0 rgB1	∫∕Ωøerlock	a 1⁄20∄f 50 29
301	Strategies to Reduce Bleeding Among Patients with Ischemic Heart Disease Treated with Antiplatelet Therapies. American Journal of Cardiology, 2009, 104, 60C-63C.	1.6	11
302	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal, 2009, 158, 881-886.e1.	2.7	32
303	Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. Current Medical Research and Opinion, 2009, 25, 413-420.	1.9	18
304	Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interventional Cardiology, 2009, 1, 51-62.	0.0	12
305	Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2008, 1, 379-386.	2.9	474
306	Bleeding after antithrombotic therapy in patients with acute ischemic heart disease. Journal of Thrombosis and Thrombolysis, 2008, 26, 175-182.	2.1	8

#	Article	IF	CITATIONS
307	International Variation in the Use of Blood Transfusion in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 25-29.e2.	1.6	49
308	The Editor's Roundtable: Management and Treatment of Non-ST-Segment Elevation in Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 1580-1598.	1.6	2
309	Major bleeding: management and risk reduction in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2008, 9, 1869-1883.	1.8	8
310	Association between bleeding, blood transfusion, and costs among patients with non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 155, 369-374.	2.7	61
311	Transfusion practice and outcomes in non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 155, 1047-1053.	2.7	96
312	Clopidogrel use and bleeding after coronary artery bypass graft surgery. American Heart Journal, 2008, 156, 886-892.	2.7	97
313	Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding. Circulation, 2008, 118, 2139-2145.	1.6	99
314	Long-term Clinical Outcomes Following Coronary Stenting. Archives of Internal Medicine, 2008, 168, 1647.	3.8	14
315	Informing the Consent Process. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 7-8.	2.2	5
316	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2007, 28, 1193-1204.	2.2	253
317	Anemia in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2007, 7, 225-233.	2.2	1
318	The Challenge of Defining Bleeding Among Patients with Acute Coronary Syndromes. Clinical Cardiology, 2007, 30, II16-II23.	1.8	10
319	A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 47, 809-816.	2.8	283
320	Patterns and outcomes of drug-eluting coronary stent use in clinical practice. American Heart Journal, 2006, 152, 321-326.	2.7	62
321	Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. Journal of Thrombosis and Thrombolysis, 2006, 21, 167-174.	2.1	77
322	On- Versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice (Report from the) Tj ETQq0 0 0 rgB1 Cardiology, 2006, 97, 1478-1481.	/Overloch 1.6	8 10 Tf 50 14 83
323	Clinical outcomes with drug-eluting stents following atheroablation therapies. Journal of Invasive Cardiology, 2006, 18, 393-6.	0.4	3
324	Bleeding as a predictor of mortality risk. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 3, S12-8.	1.4	0

Bleeding as a predictor of mortality risk. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 3, S12-8. 324 1.4

#	Article	lF	CITATIONS
325	Impact of Bleeding Severity on Clinical Outcomes Among Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2005, 96, 1200-1206.	1.6	598
326	The Implications of Blood Transfusions for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1490-1495.	2.8	201
327	Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1555.	7.4	894
328	Socioeconomic Status and Outcome Following Acute Myocardial Infarction in Elderly Patients. Archives of Internal Medicine, 2004, 164, 1128.	3.8	94
329	Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. American Journal of Cardiology, 2003, 91, 936-940.	1.6	71
330	Poverty, process of care, and outcome in acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 1948-1954.	2.8	64
331	Lessons Learned From Clinical Trials. Critical Pathways in Cardiology, 2003, 2, 55-59.	0.5	0
332	Controversies Surrounding the Use of Glycoprotein IIb/IIIa Inhibitors. Critical Pathways in Cardiology, 2003, 2, 231-238.	0.5	0